We use our own cookies and third-party cookies to improve our services and analyse the browsing habits of our users. Continuing to browse our sites implies full acceptance of their use. You can change your cookie setting or get more information here

News

06.03.18

Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis
Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis

Laboratoris Sanifit S.L., the BIOIB's clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today the... [+]

31.01.18

You can wath now the videos of BIOIB's IBTalk'17 on genetics and medicine

The last IBTalk of 2017 discussed, in a relaxed and close format, several topics such as the present limitations that genetics faces as a... [+]

14.12.17

Sanifit appoints Alexander M. Gold, M.D., F.A.C.C. as Chief Medical Officer and President of its US subsidiary

Former SVP and Head of Clinical Development at Portola Pharmaceuticals appointed as Chief Medical OfficerLaboratoris Sanifit S.L., a clinical-stage... [+]

13.12.17

Succes of BIOIB’s IBTalk on the future of genetics in medicine
Succes of BIOIB’s IBTalk on the future of genetics in medicine

The potential of genetics in diagnosis together with the need to include this discipline in the medical practice and to bring it closer to society... [+]

04.12.17

IB Talk sobre el futuro de la genética en la medicina
IB Talk sobre el futuro de la genética en la medicina

BIOIB organiza la próxima IBTalk'17 que girará en torno al papel futuro de la genética en la medicina. Se abordarán temas de gran relevancia como... [+]

10.11.17

Sanifit awarded as the largest investor in research and innovation in the Parc Bit
Sanifit awarded as the largest investor in research and innovation in the Parc Bit

The biopharmaceutical firm, partner of BIOIB, has been recognised for its effort in R&I during the celebration of the fisrt 15 years of existence... [+]